Schlosspark-Klinik, University Medicine Berlin, Internal Medicine II, Rheumatology, Berlin, Germany.
Ann Med. 2013 Jun;45(4):357-63. doi: 10.3109/07853890.2013.771986. Epub 2013 May 8.
Tocilizumab is a highly effective therapeutic agent for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. Furthermore, a large amount of case study data reveals that tocilizumab can be an effective therapy for not only rheumatoid arthritis but also for other mostly rare inflammatory rheumatic diseases. By blocking the interleukin-6 pathway tocilizumab can be a useful therapeutic alternative when conventional treatment fails. It is successful in treating diseases such as the adult-onset Still's disease, amyloidosis, giant cell arteritis, multiple myeloma, polymyalgia rheumatica, relapsing polychondritis, remitting seronegative symmetrical synovitis with pitting edema-syndrome, systemic lupus erythematosus, systemic sclerosis, and Takayasu arteritis. Studies underway are now recruiting patients to acquire further data on treating patients with non-rheumatic arthritis, inflammatory diseases. This review focuses on tocilizumab as a promising agent for treating rare and orphan diseases in rheumatology for which no satisfactory treatment is yet available.
托珠单抗是一种治疗类风湿关节炎和全身幼年特发性关节炎的高效治疗药物。此外，大量病例研究数据表明，托珠单抗不仅对类风湿关节炎有效，而且对其他大多数罕见的炎症性风湿病也有效。通过阻断白细胞介素-6 途径，当常规治疗失败时，托珠单抗可以成为一种有用的治疗选择。它在治疗成人斯蒂尔病、淀粉样变性、巨细胞动脉炎、多发性骨髓瘤、风湿性多肌痛、复发性多软骨炎、缓解性血清阴性对称性滑膜炎伴凹陷性水肿综合征、系统性红斑狼疮、系统性硬化症和 Takayasu 动脉炎等疾病方面取得了成功。目前正在进行的研究正在招募患者，以获得更多关于治疗非风湿性关节炎、炎症性疾病患者的数据。本综述重点介绍了托珠单抗作为一种有前途的药物，用于治疗风湿学中尚无满意治疗方法的罕见和孤儿疾病。
